首页|Second Affiliated Hospital Reports Findings in Personalized Medicine (Machine le arning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy)

Second Affiliated Hospital Reports Findings in Personalized Medicine (Machine le arning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy)

扫码查看
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Drugs and Therapies-Personalized Medicine is the subject of a report. According to news reporting ou t of Shanghai, People's Republic of China, by NewsRx editors, research stated, " Cancer cell growth, metastasis, and drug resistance pose significant challenges in the management of lung adenocarcinoma (LUAD). However, there is a deficiency in optimal predictive models capable of accurately forecasting patient prognoses and guiding the selection of targeted treatments." Our news journalists obtained a quote from the research from Second Affiliated H ospital, "Programmed cell death (PCD) pathways play a pivotal role in the develo pment and progression of various cancers, offering potential as prognostic indic ators and drug sensitivity markers for LUAD patients. The development and valida tion of predictive models were conducted by integrating 13 PCD patterns with com prehensive analysis of bulk RNA, single-cell RNA transcriptomics, and pertinent clinicopathological details derived from TCGA-LUAD and six GEO datasets. Utilizi ng the machine learning algorithms, we identified ten critical differentially ex pressed genes associated with PCD in LUAD, namely CHEK2, KRT18, RRM2, GAPDH, MMP 1, CHRNA5, TMPRSS4, ITGB4, CD79A, and CTLA4. Subsequently, we conducted a progra mmed cell death index (PCDI) based on these genes across the aforementioned coho rts and integrated this index with relevant clinical features to develop several prognostic nomograms. Furthermore, we observed a significant correlation betwee n the PCDI and immune features in LUAD, including immune cell infiltration and t he expression of immune checkpoint molecules. Additionally, we found that patien ts with a high PCDI score may exhibit resistance to immunotherapy and standard a djuvant chemotherapy regimens; however, they may benefit from other FDA-supporte d drugs such as docetaxel and dasatinib."

ShanghaiPeople's Republic of ChinaAs iaAdenocarcinomaCancerCyborgsDrugs and TherapiesEmerging TechnologiesHealth and MedicineLung CancerLung Diseases and ConditionsMachine Learnin gOncologyPersonalized MedicinePersonalized Therapy

2024

Robotics & Machine Learning Daily News

Robotics & Machine Learning Daily News

ISSN:
年,卷(期):2024.(Mar.7)